A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

J. C. Mansfield; M. Parkes; A. B. Hawthorne; A. Forbes; C. S. J. Probert; R. C. Perowne; A. Cooper; J. B. Zeldis; D. C. Manning; C. J. Hawkey

doi:10.1111/j.1365-2036.2007.03385.x

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

J. C. Mansfield, M. Parkes, A. B. Hawthorne, A. Forbes, C. S. J. Probert, R. C. Perowne, A. Cooper, J. B. Zeldis, D. C. Manning, C. J. Hawkey

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

Original language	English
Pages (from-to)	421-430
Number of pages	10
Journal	Alimentary Pharmacology and Therapeutics
Volume	26
Issue number	3
DOIs	https://doi.org/10.1111/j.1365-2036.2007.03385.x
Publication status	Published - 1 Aug 2007

Keywords

Adolescent
Adult
Aged
Crohn Disease
Double-Blind Method
Female
Humans
Immunosuppressive Agents
Male
Middle Aged
Placebos
Severity of Illness Index
Thalidomide
Treatment Outcome
Venous Thrombosis

Access to Document

10.1111/j.1365-2036.2007.03385.x

Cite this

Mansfield, J. C., Parkes, M., Hawthorne, A. B., Forbes, A., Probert, C. S. J., Perowne, R. C., Cooper, A., Zeldis, J. B., Manning, D. C., & Hawkey, C. J. (2007). A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. Alimentary Pharmacology and Therapeutics, 26(3), 421-430. https://doi.org/10.1111/j.1365-2036.2007.03385.x

Mansfield, J. C. ; Parkes, M. ; Hawthorne, A. B. ; Forbes, A. ; Probert, C. S. J. ; Perowne, R. C. ; Cooper, A. ; Zeldis, J. B. ; Manning, D. C. ; Hawkey, C. J. / A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. In: Alimentary Pharmacology and Therapeutics. 2007 ; Vol. 26, No. 3. pp. 421-430.

@article{972b80b46e7c449db401f55fc6aca744,

title = "A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease",

abstract = "Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.",

keywords = "Adolescent, Adult, Aged, Crohn Disease, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Male, Middle Aged, Placebos, Severity of Illness Index, Thalidomide, Treatment Outcome, Venous Thrombosis",

author = "Mansfield, {J. C.} and M. Parkes and Hawthorne, {A. B.} and A. Forbes and Probert, {C. S. J.} and Perowne, {R. C.} and A. Cooper and Zeldis, {J. B.} and Manning, {D. C.} and Hawkey, {C. J.}",

year = "2007",

month = aug,

day = "1",

doi = "10.1111/j.1365-2036.2007.03385.x",

language = "English",

volume = "26",

pages = "421--430",

journal = "Alimentary Pharmacology and Therapeutics",

issn = "0269-2813",

publisher = "Wiley",

number = "3",

}

Mansfield, JC, Parkes, M, Hawthorne, AB, Forbes, A, Probert, CSJ, Perowne, RC, Cooper, A, Zeldis, JB, Manning, DC & Hawkey, CJ 2007, 'A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease', Alimentary Pharmacology and Therapeutics, vol. 26, no. 3, pp. 421-430. https://doi.org/10.1111/j.1365-2036.2007.03385.x

A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease. / Mansfield, J. C.; Parkes, M.; Hawthorne, A. B.; Forbes, A.; Probert, C. S. J.; Perowne, R. C.; Cooper, A.; Zeldis, J. B.; Manning, D. C.; Hawkey, C. J.

In: Alimentary Pharmacology and Therapeutics, Vol. 26, No. 3, 01.08.2007, p. 421-430.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - A randomized, double-blind, placebo-controlled trial of lenalidomide in the treatment of moderately severe active Crohn's disease

AU - Mansfield, J. C.

AU - Parkes, M.

AU - Hawthorne, A. B.

AU - Forbes, A.

AU - Probert, C. S. J.

AU - Perowne, R. C.

AU - Cooper, A.

AU - Zeldis, J. B.

AU - Manning, D. C.

AU - Hawkey, C. J.

PY - 2007/8/1

Y1 - 2007/8/1

N2 - Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

AB - Therapy targeted at tumour necrosis factor-alpha has an established role in Crohn's disease. Lenalidomide, an analogue of thalidomide, is an oral immunomodulatory agent with powerful antitumour necrosis factor-alpha properties. It is licensed for myeloma and myelodysplastic syndrome. Based upon reports of thalidomide efficacy, lenalidomide was evaluated in Crohn's disease.

KW - Adolescent

KW - Adult

KW - Aged

KW - Crohn Disease

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Immunosuppressive Agents

KW - Male

KW - Middle Aged

KW - Placebos

KW - Severity of Illness Index

KW - Thalidomide

KW - Treatment Outcome

KW - Venous Thrombosis

U2 - 10.1111/j.1365-2036.2007.03385.x

DO - 10.1111/j.1365-2036.2007.03385.x

M3 - Article

C2 - 17635377

VL - 26

SP - 421

EP - 430

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 3

ER -